Association of Lupus Anticoagulant status with Disease Course in SARS-CoV-2 (COVID-19) Infection
Background: We investigated the importance of lupus anticoagulant (LA) in patients with SARS-CoV-2. Methods: Medical records of 41 SARS-CoV-2 infected patients were reviewed. Patients were classified into two groups according to the frequency of positive LA test results: “LA (−)” and “LA (+) ≥1” (LA...
Main Authors: | Suhyeon Woo MD, Bohyun Kim MD, PhD, Nam Hun Heo MS, Min-sun Kim MD, Young Ahn Yoon MD, Young-Jin Choi MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-09-01
|
Series: | Clinical and Applied Thrombosis/Hemostasis |
Online Access: | https://doi.org/10.1177/10760296221127276 |
Similar Items
-
Prevalence and Impact of Lupus Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation
by: Andrea Kornfehl MD, et al.
Published: (2023-10-01) -
Routine Lupus Anticoagulant Sensitive aPTT Testing Can Prevent Unnecessary LA Testing
by: Bob Smit PhD, et al.
Published: (2023-06-01) -
Subacute cutaneous lupus erythematosus after mRNA-based SARS-CoV-2 vaccination
by: Sarah Rimmer, BS, et al.
Published: (2023-03-01) -
Direct Oral Anticoagulants in Patients With Active Cancer
by: Jolanda Sabatino, MD, PhD, et al.
Published: (2020-09-01) -
Koronavirus SARS-CoV-2
by: Ksenija Geršak, MD, PhD
Published: (2020-04-01)